Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was bought at an average price of $3.97 per share, with a total value of $19,850.00. Following the purchase, the director now directly owns 3,046,550 shares in the company, valued at approximately $12,094,803.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

James George Robinson also recently made the following trade(s):

  • On Wednesday, August 2nd, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average price of $3.79 per share, with a total value of $18,950.00.
  • On Thursday, August 3rd, James George Robinson bought 10,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average price of $3.73 per share, with a total value of $37,300.00.
  • On Tuesday, August 1st, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average price of $3.72 per share, with a total value of $55,800.00.
  • On Thursday, July 6th, James George Robinson bought 3,000 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average price of $3.92 per share, with a total value of $11,760.00.
  • On Friday, July 7th, James George Robinson bought 11,500 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average price of $4.00 per share, with a total value of $46,000.00.
  • On Wednesday, June 28th, James George Robinson bought 8,500 shares of Nymox Pharmaceutical Corporation stock. The shares were acquired at an average price of $4.09 per share, with a total value of $34,765.00.
  • On Monday, June 26th, James George Robinson purchased 15,000 shares of Nymox Pharmaceutical Corporation stock. The shares were purchased at an average cost of $3.80 per share, for a total transaction of $57,000.00.
  • On Tuesday, June 20th, James George Robinson purchased 5,000 shares of Nymox Pharmaceutical Corporation stock. The shares were purchased at an average cost of $3.76 per share, for a total transaction of $18,800.00.
  • On Monday, June 19th, James George Robinson purchased 5,000 shares of Nymox Pharmaceutical Corporation stock. The shares were purchased at an average cost of $3.79 per share, for a total transaction of $18,950.00.
  • On Wednesday, June 21st, James George Robinson purchased 15,000 shares of Nymox Pharmaceutical Corporation stock. The shares were purchased at an average cost of $3.77 per share, for a total transaction of $56,550.00.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) opened at 3.66 on Monday. The firm’s 50-day moving average price is $3.96 and its 200 day moving average price is $3.79. Nymox Pharmaceutical Corporation has a 52-week low of $1.62 and a 52-week high of $5.79. The firm’s market cap is $184.64 million.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: Nymox Pharmaceutical Corporation (NYMX) Director Purchases 5,000 Shares of Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/07/nymox-pharmaceutical-corporation-nymx-director-purchases-19850-00-in-stock-updated-updated-updated.html.

Separately, ValuEngine lowered Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 24th.

Several hedge funds have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $134,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $222,000. Bank of New York Mellon Corp acquired a new stake in shares of Nymox Pharmaceutical Corporation during the second quarter valued at approximately $323,000. Finally, Wedbush Securities Inc. boosted its stake in shares of Nymox Pharmaceutical Corporation by 30.6% in the second quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock valued at $1,033,000 after buying an additional 55,000 shares during the last quarter. Institutional investors own 1.78% of the company’s stock.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Stock Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related stocks with our FREE daily email newsletter.